Fubotv earnings beat by $0.10, revenue topped estimates
BROSSARD, Quebec - Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Canadian company specializing in early detection of health issues through AI technology, has engaged Allele Capital Partners, LLC for advisory services. The company’s stock, currently trading at $0.15, has seen a challenging year with a 58% decline over the past 12 months according to InvestingPro data. Allele will offer capital markets advisory and social media support to Diagnos for an initial trial period starting May 22, 2025, with the potential for a nine-month extension.
The agreement entitles Allele to a monthly fee of US$7,500, with Diagnos retaining the option to terminate with a 30-business day notice during the trial period ending August 22, 2025. The renewal of the contract, upon written confirmation from Diagnos, would maintain the same monthly compensation. InvestingPro analysis indicates the company’s overall financial health score is rated as WEAK, with revenue of $90,000 in the last twelve months. Allele, based in Southeast Florida, operates independently from Diagnos and currently holds no direct or indirect interest in Diagnos securities.
Diagnos aims to refine its business strategy with Allele’s assistance to optimize milestones and capital market objectives, ultimately seeking to enhance shareholder value. The collaboration is contingent upon approval from the TSX Venture Exchange.
Diagnos leverages AI to aid healthcare professionals in the early detection of eye-related health problems, striving to improve diagnostic precision and patient outcomes worldwide. The company’s forward-looking statements indicate that actual results may differ from anticipated outcomes and are subject to change. This news is based on a press release statement from Diagnos Inc.
In other recent news, Diagnos Inc. has announced the opening of its first U.S. office in Fort Lauderdale, Florida. This expansion aligns with the company’s strategic vision to engage with potential clients and demonstrate its AI technology platform to professionals in the ophthalmic and optometry sectors. The move into Florida was influenced by the state’s favorable business environment and skilled workforce. Diagnos is also in the process of hiring its first U.S. employees to support this new office. Additionally, the company is working towards securing U.S. FDA certification for significant updates to its AI-assisted fundus image analysis platform, which is designed to aid healthcare professionals in diagnosing eye health issues. In corporate governance news, Diagnos announced the resignation of Mr. Francis Bellido from the board of directors and his role as chairman of the audit committee. The board expressed gratitude for Bellido’s contributions, as he continues his role as CEO and director of Quantum eMotion. Furthermore, Diagnos has engaged DS Market Solutions Inc. to maintain an orderly market for its securities, with services expected to begin on April 1, 2025, pending TSX Venture Exchange approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.